| Project/Area Number |
18K07918
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | International University of Health and Welfare |
|---|
Principal Investigator |
Higuchi Hajime 国際医療福祉大学, 医学部, 主任教授 (20306682)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 克仁 国際医療福祉大学, 国際医療福祉大学三田病院, 教授 (40211338)
潮見 隆之 国際医療福祉大学, 医学部, 教授 (80348797)
|
|---|
| Project Period (FY) |
2018-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 膵癌 / オルガノイド / EUS-TA / クリニカルシーケンス / ゲノム医療 / EUS-FNA / ゲノムシーケンス / 多領域シーケンス / マイクロダイセクション |
|---|
| Outline of Final Research Achievements |
Clinical sequence is expected to pancreatic cancer precision medicine. We investigated the technology to obtain pancreatic cancer DNA for clinical sequencing. Although we developed an organoid culture system derived from pancreatic cancer tissue, its usefulness in clinical sequencing has not yet been established. In contrast, we found a endoscopic ultrasonography-guided tissue acquisition (EUS-TA) with 19 gauge needle effectively obtained tissue samples. Whole exome sequencing was succeeded in 100% of the 5 cases tested. In the future, it is necessary to improve the efficiency of tissue collection using EUS-TA and establish a method to collect high-quality DNA samples that can be used for whole exome analysis or whole genome analysis.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、治療困難かつ予後不良な悪性腫瘍である膵癌に対するprecision medicineの精度向上のための基礎的検討である。KRASがドライバー遺伝子として大部分を占める膵癌においては、現時点ではクリニカルシーケンスの意義は大きくはない。しかしながら、新規薬剤（抗KRAS薬を含む）の開発に伴い、感受性因子あるいは抵抗性因子の探索や併存するドライバー変異の探索など、将来的に重要性が増すと考えられる。
|
